L
Lycia Therapeutics LYCA
$31.20
−4.96%
Nov 13
1W
1M
Posts
No posts about LYCA yet.
About Lycia Therapeutics, Inc. Common Stock
Lycia Therapeutics is a clinical-stage biotech in South San Francisco. Its LYTAC platform builds drugs that clear disease-causing proteins from the blood, starting with allergy (IgE) and Graves' disease. It has no approved products, so it is funded by investors, an IPO on Nasdaq in October 2026 and a collaboration with Lilly.